914 related articles for article (PubMed ID: 27888421)
1. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
3. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of the prognostic staging system in the 8th edition of the American Joint Committee on Cancer for triple-negative breast cancer: a SEER population-based analysis.
Liu YY; Yu TJ; Liu GY
Future Oncol; 2019 Feb; 15(4):391-400. PubMed ID: 30620221
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database.
Luo SP; Wu QS; Chen H; Wang XX; Chen QX; Zhang J; Song CG
J Surg Res; 2020 Mar; 247():211-219. PubMed ID: 31706539
[TBL] [Abstract][Full Text] [Related]
6. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
7. Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
Li X; Zhang Y; Meisel J; Jiang R; Behera M; Peng L
Breast Cancer Res Treat; 2018 Sep; 171(2):303-313. PubMed ID: 29948405
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study.
Lin S; Liu C; Tao Z; Zhang J; Hu X
Breast; 2020 Feb; 49():157-164. PubMed ID: 31812891
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Survival of Triple-Negative Breast Cancer in Different Stages: A SEER Population Based Research Referring to Clinicopathological Factors.
Chen SS; Tang SC; Li K; Wu J; Li X; Ren H; Sun X
Cancer Invest; 2020 Nov; 38(10):549-558. PubMed ID: 32998588
[TBL] [Abstract][Full Text] [Related]
10. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer.
He M; Zhang JX; Jiang YZ; Chen YL; Yang HY; Tang LC; Shao ZM; Di GH
Oncotarget; 2017 Jul; 8(27):44870-44880. PubMed ID: 28496004
[TBL] [Abstract][Full Text] [Related]
11. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database.
Chen QX; Wang XX; Lin PY; Zhang J; Li JJ; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(3):4773-4780. PubMed ID: 27999201
[TBL] [Abstract][Full Text] [Related]
12. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
13. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113872
[No Abstract] [Full Text] [Related]
17. Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
Park S; Moon BI; Oh SJ; Lee HB; Seong MK; Lee S; Byun KD; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Feb; 173(3):679-691. PubMed ID: 30390214
[TBL] [Abstract][Full Text] [Related]
18. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc.
Cui J; Jiang H
Medicine (Baltimore); 2019 Oct; 98(40):e17370. PubMed ID: 31577739
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
